Related Experiment Video

Updated: Jul 3, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Intravascular hemolysis following low dose daily rifampin

Cindy E Neunert1, Geeta S Paranjape, Scott Cameron

  • 1Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390-9063, USA. cindy.neunert@utsouthwestern.edu

Pediatric Blood & Cancer
|August 6, 2008
PubMed

Insights

Low-dose rifampin can cause hemolysis in children treated for methicillin-resistant Staphylococcus aureus (MRSA). Physicians should monitor for this rare but serious side effect, even with standard treatment regimens.

Area of Science:

  • Pediatric Hematology
  • Infectious Diseases
  • Pharmacology

Background:

  • Methicillin-resistant Staphylococcus aureus (MRSA) infections are a growing concern in pediatric populations.
  • Rifampin is an antibiotic commonly used to treat MRSA infections.
  • Hemolysis is a rare but serious potential side effect of rifampin therapy.

Observation:

  • Two pediatric cases of rifampin-induced hemolysis were observed.
  • Patients received low daily doses of rifampin for MRSA treatment.
  • Hemolysis occurred despite the low dosage of the antibiotic.

Findings:

  • Rifampin therapy, even at low daily doses, can precipitate hemolysis in pediatric patients.
  • The risk of hemolysis should be considered in children receiving rifampin for MRSA.
  • This adverse drug reaction highlights the importance of vigilant monitoring during antibiotic treatment.

Implications:

  • Clinicians should maintain a high index of suspicion for hemolysis in pediatric patients on rifampin.
  • Early recognition and management of rifampin-induced hemolysis are crucial.
  • Further research may be warranted to elucidate the mechanisms and risk factors for this adverse event.

Related Concept Videos

Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Lifecycle of Erythrocytes01:22

Lifecycle of Erythrocytes

Erythrocytes, also known as red blood cells, constantly move through blood capillaries. As a result, they damage their plasma membrane due to the continuous friction. Typically, after 100 to 120 days, erythrocytes become rigid and fragile as they wear out. As they pass through small vessels in the spleen and liver, they can get trapped and break apart into fragments.
The resident phagocytic macrophages deal with these damaged cells by engulfing them and separating their globin and heme groups.